Outlook Therapeutics Inc (NASDAQ:OTLK) has a beta value of 0.61 and has seen 20.07 million shares traded in the recent trading session. The company, currently valued at $28.02M, closed the recent trade at $1.18 per share which meant it lost -$3.71 on the day or -75.78% during that session. The OTLK stock price is -988.98% off its 52-week high price of $12.85 and -290.68% below the 52-week low of $4.61. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.29 million shares traded. The 3-month trading volume is 277.48K shares.
The consensus among analysts is that Outlook Therapeutics Inc (OTLK) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 5 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.9.
Outlook Therapeutics Inc (NASDAQ:OTLK) trade information
Sporting -75.78% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the OTLK stock price touched $1.18 or saw a rise of 77.69%. Year-to-date, Outlook Therapeutics Inc shares have moved -84.97%, while the 5-day performance has seen it change -77.57%. Over the past 30 days, the shares of Outlook Therapeutics Inc (NASDAQ:OTLK) have changed -79.37%. Short interest in the company has seen 3.4 million shares shorted with days to cover at 11.43.
Outlook Therapeutics Inc (OTLK) estimates and forecasts
Figures show that Outlook Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -83.60% over the past 6 months, with this year growth rate of 20.00%, compared to 17.60% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 52.49% over the past 5 years.
OTLK Dividends
Outlook Therapeutics Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Outlook Therapeutics Inc (NASDAQ:OTLK)’s Major holders
Insiders own 35.58% of the company shares, while shares held by institutions stand at 35.65% with a share float percentage of 55.34%. Investors are also buoyed by the number of investors in a company, with Outlook Therapeutics Inc having a total of 95.0 institutions that hold shares in the company. The top two institutional holders are ROSALIND ADVISORS, INC. with over 0.45 million shares worth more than $3.32 million. As of 2024-06-30, ROSALIND ADVISORS, INC. held 3.1534% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Extended Market Index Fund and Vanguard Total Stock Market Index Fund. As of Jun 30, 2024, the former fund manager holds about 1.20% shares in the company for having 283.49 shares of worth $0.44 million while later fund manager owns 204.51 shares of worth $0.32 million as of Jun 30, 2024, which makes it owner of about 0.86% of company’s outstanding stock.
